A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT_CML 1.

Heibl, S; Buxhofer-Ausch, V; Schmidt, S; Webersinke, G; Lion, T; Piringer, G; Kuehr, T; Wolf, D; Melchardt, T; Greil, R; Thaler, J

View this publication in the PUBMED database